Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD79b CAR T cells JV-213

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD79b CAR-T cells JV-213 target and bind to CD79b-expressing tumor cells, thereby inducing selective toxicity in CD79b-expressing tumor cells. CD79b, a critical receptor for successful B-cell development and part of the B-cell receptor (BCR) signaling complex, is widely expressed in certain subtypes of B-cell lymphomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD79b-CAR T cells JV-213
autologous CD79b-targeting CAR T cells JV-213
Code name:JV 213
JV-213
JV213
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search